Strategic objectives

• Development of new therapies for the prevention of bronchopulmonary dysplasia.
• Evaluation of new therapies in pulmonary arterial hypertension (PAH).
• Evaluation of new drugs in paediatrics.
• Prognosis and quality of life of congenital cardiopathies in the medium and long term.
• Genetic mapping of diabetes mellitus, type 1.
• Development, implementation and dissemination of new technologies in diabetes mellitus, type 1 in childhood and adolescence.
• New insulins in diabetes mellitus, type 1 in childhood and adolescence.
• Lifestyle, prevention and treatment in child obesity.
• Epidemiology and genetic analysis of frequent diseases: pseudohypoparathyroidism (PHP GROUP), monogenic diabetes.
• Epidemiological studies on efficacy and safety in children with treatment with growth hormone.
• Hyperandrogenism and type 1 diabetes.

Research lines

• Pulmonary arterial hypertension.
• Cell therapy in bronchopulmonary dysplasia.
• Markers for prediction of the risk of developing bronchopulmonary dysplasia.
• New drug safety approaches in the paediatric population.
• Adolescent and adult congenital cardiopathies.
• New technologies in type 1 diabetes.
• New drugs in type 1 diabetes in childhood and adolescence.
• Epidemiology and safety of paediatric hospital infections.
• Hyperandrogenism and diabetes mellitus, type 1.
• Pituitary tumours in children and adolescents.